FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311292024> ?p ?o ?g. }

• W4311292024 endingPage "5048" @default.
• W4311292024 startingPage "5029" @default.
• W4311292024 abstract "Uterine endometrial cancer (EC) incidence and deaths are on the rise. Hormone therapy, a traditional treatment regimen for this disease, uses progesterone and its synthetic analogue, progestin, to induce cell differentiation, apoptosis, and inhibition of invasion. This therapy is highly effective for progesterone receptor (PR) positive tumors in the short term. However, responsiveness decreases over time due to loss of PR expression; acquired resistance leads to treatment failure and poor prognosis. Primary resistance occurs in advanced, PR-negative tumors. Regardless, progestin therapy can be effective if the PR downregulation mechanism is reversed and if functional PR expression is restored. Using histone deacetylase inhibitors (HDACi), we inhibited cell proliferation in three EC cell lines and restored functional PR expression at the mRNA and protein levels. Two HDACi were tested using an endometrial xenograft tumor model: entinostat, an oral drug, and romidepsin, an IV drug. In vitro and in vivo studies support that entinostat decreased EC tumor growth, induced differentiation, and increased expression of the PR-targeted gene, PAEP. These findings supported the approval of a new NIH NCTN clinical trial, NRG-GY011, which concluded that dual treatment of MPA and entinostat, decreased expression of the proliferation marker, Ki67, but did not increase PR expression relative to single treatment with MPA in this short-term study. Therefore, a more potent HDACi, romidepsin, was investigated. Romidepsin treatment inhibited tumor growth and enhanced progestin treatment efficacy. More importantly, PR, PAEP, and KIAA1324 expressions were upregulated. Using a chromatin immunoprecipitation assay, we verified that HDACi can reverse PR downregulation mechanisms in mice models. Other potential drug efficacy markers, such as CD52, DLK1, GALNT9, and GNG2, were identified by transcriptome analysis and verified by q-PCR. Many of the upregulated drug efficacy markers predict favorable patient outcomes, while downregulated genes predict worse survival. Here, our current data suggests that romidepsin is a more potent HDACi that has the potential to achieve more robust upregulation of PR expression and may be a more promising candidate for future clinical trials." @default.
• W4311292024 created "2022-12-25" @default.
• W4311292024 creator A5000348773 @default.
• W4311292024 creator A5006719764 @default.
• W4311292024 creator A5011828487 @default.
• W4311292024 creator A5014011362 @default.
• W4311292024 creator A5023118977 @default.
• W4311292024 creator A5030980350 @default.
• W4311292024 creator A5031164821 @default.
• W4311292024 creator A5037629068 @default.
• W4311292024 creator A5042316902 @default.
• W4311292024 creator A5048762334 @default.
• W4311292024 creator A5051177198 @default.
• W4311292024 creator A5056465234 @default.
• W4311292024 creator A5075341219 @default.
• W4311292024 creator A5077633171 @default.
• W4311292024 creator A5087108704 @default.
• W4311292024 creator A5088579856 @default.
• W4311292024 date "2022-01-01" @default.
• W4311292024 modified "2023-09-27" @default.
• W4311292024 title "Enhancing progestin therapy via HDAC inhibitors in endometrial cancer." @default.
• W4311292024 cites W1564613369 @default.
• W4311292024 cites W1591382993 @default.
• W4311292024 cites W1834297004 @default.
• W4311292024 cites W1861033863 @default.
• W4311292024 cites W1874720664 @default.
• W4311292024 cites W1941055066 @default.
• W4311292024 cites W1970171858 @default.
• W4311292024 cites W1974171707 @default.
• W4311292024 cites W1986757639 @default.
• W4311292024 cites W2007139310 @default.
• W4311292024 cites W2024112030 @default.
• W4311292024 cites W2040762618 @default.
• W4311292024 cites W2045327531 @default.
• W4311292024 cites W2050276596 @default.
• W4311292024 cites W2051890772 @default.
• W4311292024 cites W2057358066 @default.
• W4311292024 cites W2088710838 @default.
• W4311292024 cites W2098400976 @default.
• W4311292024 cites W2101691277 @default.
• W4311292024 cites W2105835610 @default.
• W4311292024 cites W2111163389 @default.
• W4311292024 cites W2129680759 @default.
• W4311292024 cites W2134280534 @default.
• W4311292024 cites W2148131050 @default.
• W4311292024 cites W2154981816 @default.
• W4311292024 cites W2190043116 @default.
• W4311292024 cites W2229860828 @default.
• W4311292024 cites W2267939324 @default.
• W4311292024 cites W2345797230 @default.
• W4311292024 cites W2519511762 @default.
• W4311292024 cites W2551703404 @default.
• W4311292024 cites W2559244128 @default.
• W4311292024 cites W2591958823 @default.
• W4311292024 cites W2615966397 @default.
• W4311292024 cites W2709898312 @default.
• W4311292024 cites W2724336500 @default.
• W4311292024 cites W2749613778 @default.
• W4311292024 cites W2771812963 @default.
• W4311292024 cites W2789734005 @default.
• W4311292024 cites W2889640389 @default.
• W4311292024 cites W2909147518 @default.
• W4311292024 cites W2937760511 @default.
• W4311292024 cites W2940244268 @default.
• W4311292024 cites W3019536871 @default.
• W4311292024 cites W3028304854 @default.
• W4311292024 cites W3041631140 @default.
• W4311292024 cites W3096377085 @default.
• W4311292024 cites W3110454612 @default.
• W4311292024 cites W3123024197 @default.
• W4311292024 cites W3130705868 @default.
• W4311292024 cites W3136128457 @default.
• W4311292024 cites W3154246057 @default.
• W4311292024 cites W4206841660 @default.
• W4311292024 cites W4221038780 @default.
• W4311292024 cites W1883437668 @default.
• W4311292024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36504895" @default.
• W4311292024 hasPublicationYear "2022" @default.
• W4311292024 type Work @default.
• W4311292024 citedByCount "0" @default.
• W4311292024 crossrefType "journal-article" @default.
• W4311292024 hasAuthorship W4311292024A5000348773 @default.
• W4311292024 hasAuthorship W4311292024A5006719764 @default.
• W4311292024 hasAuthorship W4311292024A5011828487 @default.
• W4311292024 hasAuthorship W4311292024A5014011362 @default.
• W4311292024 hasAuthorship W4311292024A5023118977 @default.
• W4311292024 hasAuthorship W4311292024A5030980350 @default.
• W4311292024 hasAuthorship W4311292024A5031164821 @default.
• W4311292024 hasAuthorship W4311292024A5037629068 @default.
• W4311292024 hasAuthorship W4311292024A5042316902 @default.
• W4311292024 hasAuthorship W4311292024A5048762334 @default.
• W4311292024 hasAuthorship W4311292024A5051177198 @default.
• W4311292024 hasAuthorship W4311292024A5056465234 @default.
• W4311292024 hasAuthorship W4311292024A5075341219 @default.
• W4311292024 hasAuthorship W4311292024A5077633171 @default.
• W4311292024 hasAuthorship W4311292024A5087108704 @default.
• W4311292024 hasAuthorship W4311292024A5088579856 @default.
• W4311292024 hasConcept C101762097 @default.

• next